GIM Raises US$20 Million Series A as Agentic Investing Enters Live Execution

GIM Raises US$20 Million Series A as Agentic Investing Enters Live Execution

HONG KONG, BEIJING and SHANGHAI, July 9, 2026 /PRNewswire/ -- Grace Investment Machine ("GIM"), an AI-native investment technology company building agentic systems for capital markets, today announced the close of its US$20 million Series A...

Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform

Pictor® Holdings Inc. Secures $7.5 Million Bridge Round to Accelerate Commercialization of Targeted Proteomic Platform

Investment brings Pictor's total capital raised to approximately $30 million, supporting expanded U.S. and international commercialization efforts CARLSBAD, Calif., June 30, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic...

Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence

Xellar Raises $50 Million Series A Financing to Build the Future of 3D Bio Intelligence

Financing will accelerate the development of human-relevant biological data infrastructure, virtual cell technologies, and next-generation drug discovery BOSTON, June 30, 2026 /PRNewswire/ -- Xellar Biosystems today announced the closing of $50...

Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on...

OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

SHANGHAI, Dec. 5, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100...

Model ML raises $75M In One of The Largest FinTech Series A Rounds In History to Transform Financial Services with AI Workflow Automation

Model ML raises $75M In One of The Largest FinTech Series A Rounds In History to Transform Financial Services with AI Workflow Automation

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- Model ML, the leading global AI workflow automation platform for financial services, today announced a $75 million Series A financing led by FT Partners, the global leader in FinTech investment banking. The...

Mine Vision Systems Announces $12.5 Million Series A to Accelerate Underground Mining Decision Platform

Mine Vision Systems Announces $12.5 Million Series A to Accelerate Underground Mining Decision Platform

PITTSBURGH, Nov. 5, 2025 /PRNewswire/ -- Mine Vision Systems (MVS), the leader in vision-driven mapping and analytics for underground mining, today announced a $12.5 million Series A financing led by Rockwell Venture Capital with a significant...

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

FIELD MEDICAL CLOSES $40 MILLION SERIES A FINANCING TO REDEFINE PULSED FIELD ABLATION FOR VENTRICULAR TACHYCARDIA

CARDIFF-BY-THE-SEA, Calif., April 22, 2025 /PRNewswire/ -- Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million in Series A financing. The round includes $20 million...

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept

Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with significant...

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases

BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its...

  • 1
  • 2
  • menu
    menu